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Background: Cancer patients are at increased risk for venous thromboembolism (VTE).
Objective: This monocenter cross-sectional study prospectively assessed the association between a history of ≥1 VTE
episode and the presence of pulmonary hypertension (PH) among cancer patients presenting with pulmonary or
cardiac symptoms.
Methods: A consecutive series of 583 patients underwent a diagnostic work-up for heart and lung disease. PH was
diagnosed if a patient’s peak systolic pressure gradient across the tricuspid valve was ≥35 mmHg, as measured by
echocardiography. Using multiple logistic regression analysis, the association between VTE and PH was assessed,
following adjustments for age, the presence of severe airway obstruction, atrial fibrillation and left heart diseases.
Results: The prevalence values for PH (n = 90) and a history of VTE (n = 72) were 15.4 and 12.3 %, respectively. The
median time interval between the first VTE episode and referral was 43 months. The odds of PH was higher in the
subgroup with VTE (19/72; 26.4 %) than that without VTE (71/511; 13.9 %) in the unadjusted analysis [odds ratio (OR)
2.2, 95 % confidence interval (CI) 1.2, 4.0] and the adjusted model [OR 2.4, 95 % CI 1.2, 4.5]. The risk of PH did not
depend on the time interval between VTE and referral. Older age and the presence of severe airway obstruction, atrial
fibrillation, and left heart diseases were also associated with an increased odds of PH.
Conclusion: In cancer patients presenting with cardiac or pulmonary symptoms, previous VTE is associated with an
increased risk of persistent PH.
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Cancer is a risk factor for venous thromboembolism
(VTE), which comprises deep vein thrombosis (DVT)
and pulmonary embolism (PE) [1–4]. A retrospective
cohort study suggested that cancer predisposes patients
to developing chronic thromboembolic pulmonary
hypertension (CTPH); therefore, the diagnosis of pul-
monary hypertension (PH) should prompt a search for
CTPH [5]. The presence of PH may often be overlooked
among cancer patients because fatigue, exercise intoler-
ance and general clinical deterioration are commonly
reported in both conditions. The objective of this study* Correspondence: siegfried.wieshammer@og.ortenau-klinikum.de
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of PH in patients referred for evaluation by a pulmonol-
ogist or cardiologist because of symptoms suggestive of
either lung or heart disease.Patients and methods
Patients
This monocenter cross-sectional study prospectively
included 586 consecutive patients with either a history
of cancer or active malignant disease who were referred
from primary care, oncology or radio-oncology to the
pulmonology or cardiology services of an academic
teaching hospital from May 2007 to October 2014 for
dyspnea, cough, chest pain, pulse irregularities, or
exercise intolerance. All but 8 patients were outpatients
and none was confined to bed.article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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group with the rarer of the two outcomes (i.e., presence
of PH) was well above the minimum sample size as
estimated from the rule of 10 outcomes per predictor
variable in logistic regression [6]. According to this rule,
the sample size of the PH group had to comprise ≥70
subjects to avoid over-fitting because 7 predictor vari-
ables were entered into the model.
All patients agreed to participate. We excluded 3 cases
because of missing data; thus, 583 patients with 655
malignancies were available for the final analysis. Of 72
patients with multiple tumors, 61 had different tumors.
All patients were interviewed for a history of VTE in a
standardized manner. The patient’s medical records were
reviewed to verify all self-reported VTE and tumor
diagnoses that were made at the authors' or other insti-
tutions. All patients had symptoms consistent with DVT
or PE. The PE group did not include patients with inci-
dental PE discovered during routine imaging studies [7].
A VTE was defined as cancer-related if it occurred in
the presence of active malignant disease (see Table 1 for
definition) or if a new diagnosis of active malignant
disease was made over the following year. The VTE
patients were not routinely screened for hereditary
thrombophilia.
Data from a subgroup of the study cohort were pub-
lished in a previous paper [8]. This study was approved
by the ethics committee of the Baden-Württemberg
State Chamber of Physicians and informed consent was
obtained.
Diagnostic procedures
The patients underwent an examination for heart and
lung disease that included electrocardiography, echocar-
diography, and pulmonary function testing, as previously
described [8]. Further tests were done when clinicallyTable 1 Demographic and clinical characteristics of patients with an
PE n = 48
Male:female (47.9):(52.1)
Agex, years 71.3 ± 9.6
Active malignant disease 20/48 (41.7)
Heart disease 25/48 (52.1)
Impaired left ventricular systolic function 3/48 (6.3)
Atrial fibrillation 5/48 (10.4)
Significant aortic or mitral valve disease 5/48 (10.4)
Left ventricular hypertrophy 7/48 (14.6)
No: mild to moderate: moderately severe:
≥ severe airway obstruction
(63.0):(21.7):(10.9):(4.4)
Pulmonary hypertension 16/48 (33.3)
*VTE versus No VTE subgroup
Figures in parenthesis are percentages; xmean ± standard deviation; aχ2-Test; bt-test
Active malignant disease at the time of referral: residual tumor or time interval betwindicated. The cardiologists who did the echocardio-
grams were unaware of the aim of this study.
A diagnosis of PH was made if the peak systolic pressure
gradient across the tricuspid valve was ≥35 mmHg, as
measured by continuous-wave Doppler echocardiography.
Heart disease was diagnosed based on the presence of at
least one of the following findings: (a) impaired left
ventricular systolic function [ejection fraction <50 %, as
determined using the biplane modified Simpson’s rule];
(b) atrial fibrillation; (c) significant valvular heart disease
[mild aortic stenosis (mean pressure gradient ≥20 mmHg),
moderate aortic regurgitation, moderate mitral regur-
gitation, or mild mitral stenosis]; and (d) left ventricular
hypertrophy [end-diastolic septal wall thickness ≥12 mm].
Severe airway obstruction was diagnosed if the forced
expiratory volume in 1 s (FEV1)/forced vital capacity
(FVC) ratio was <0.70 and if the FEV1 was <50 % of
predicted. The degree of obstruction was adjusted for the
degree of restriction among the patients with mixed
obstructive-restrictive lung disease [9].
Data analysis
Logistic regression analysis was used to evaluate the
association, given as an odds ratio (OR) and a 95 %
confidence interval (CI), between a history of VTE (PE)
as the primary predictor variable and the presence of PH
as the binary outcome. This association was tested in
both unadjusted and adjusted models accounting for
age, the presence of severe airway obstruction and the
above-mentioned cardiac disorders (a-d) as prospectively
selected disturbance variables. The primary predictor
variable and the 6 disturbance variables were treated as
equally weighted and independent covariates. In com-
pliance with the above-mentioned 1 in 10 rule, the odds
for PH was then additionally adjusted for the presence
of active malignant disease at the time of referral [6]. Tod without venous thromboembolism (VTE)
VTE n = 72 No VTE n = 511 p-value*
(45.8):(54.2) (54.4):(45.6) 0.17a
70.3 ± 9.8 68.1 ± 11.2 0.11b
30/72 (41.7) 192/511 (37.6) 0.50a
35/72 (48.6) 197/511 (38.6) 0.10a
4/72 (5.6) 31/511 (6.1) 1.00c
8/72 (11.1) 83/511 (16.2) 0.26a
6/72 (8.3) 40/511 (7.8) 0.88a
14/72 (19.4) 76/511 (14.9) 0.31a
(70.0):(18.6):(8.6):(2.9) (62.5):(13.8):(13.0):(10.7) 0.10a
19/72 (26.4) 71/511 (13.9) <0.01a
; cFisher’s exact test
een surgery/end of chemotherapy/radiotherapy and referral <3 months
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time-dependent, the time interval from the first VTE
episode to referral was entered into the model in a sec-
ond step. Given the exploratory nature of the study, the
results should not be interpreted as confirmatory; no
adjustment for multiple tests was made. A p-value <0.05
was considered statistically significant. The analyses
were performed using SAS, version 9.3 (SAS Institute,
Chicago, IL).
Results
We identified 90 patients with PH (15.4 %) and 72
patients (12.3 %) with a history of at least 1 VTE at the
time of referral, 48 of whom had a PE. Among the 45
patients with DVT, 93.3 % had leg DVT and 6.7 % had
arm DVT. Only 10 patients reported recurrent VTE,
and 3 patients developed VTE within 1 month prior to
referral. All 3 patients had PE, and one of them had PH.
In 51.3 % of the 72 patients, VTE was classified as
cancer-related. The median time intervals (interquartile
range) between the first VTE episode and referral
were 43 (11; 134) months in the whole VTE group
and 57 (25; 136) in the 19 patients with both VTE and
PH. The time interval between the diagnosis of the first
tumor and referral was 43 (7; 111) months in the whole
cohort. Figure 1 shows the frequency distribution of the
time intervals between the first VTE episode and the
diagnosis of the first tumor for the 34 patients in whom
VTE preceded the diagnosis of cancer or both diagnoses
coincided in time.
Table 1 lists both the clinical data and the distribution
of the pulmonary and cardiac findings in the subgroups,
with and without VTE. The data for the 48 patients with
documented PE is also given, but the between-group
comparisons were limited to the VTE versus no VTE
groups for the reasons indicated below. These two
groups were well balanced, except for the prevalence of
PH (26.4 versus 13.9 %, p <0.01). The odds of PH wasFig. 1 The frequency distribution of the time intervals between the
first VTE episode and the diagnosis of the first tumor for the 34
patients in whom VTE preceded the diagnosis of cancer or both
diagnoses coincided in time (n = 8). The median time interval
(interquartile range) was 29.0 (0.0; 416.0) monthshigher in the subgroup with VTE than that without VTE
in both the unadjusted analysis (OR 2.2, 95 % CI 1.2,
4.0) and the adjusted model (OR 2.4, 95 % CI 1.2, 4.5).
Older age (OR 1.04, 95 % CI 1.0, 1.1) and the presence
of severe airway obstruction (OR 2.6, 95 % CI 1.2, 5.4),
atrial fibrillation (OR 2.1, 95 % CI 1.2, 3.8), significant
mitral or aortic valve disease (OR 4.8, 95 % CI 2.4, 9.8)
and left ventricular hypertrophy (OR 2.2, 95 % CI 1.2,
3.9) were also associated with an increased odds of PH,
whereas the presence of impaired left ventricular func-
tion had no effect on the odds of PH (OR 0.7, 95 % CI
0.2, 1.9). Only 7 of the 35 patients with impaired left
ventricular function had PH. When the predictor
variable PE (n =48) was separately analyzed, the odds of
PH increased by 3-fold in both the unadjusted (OR 3.1,
95 % CI 1.6-6.0) and the adjusted model (OR 3.3, 95 %
CI 1.6, 6.8). The odds of PH did not depend on the
time interval between the first VTE episode and
referral (p = 0.32). The time course of the risk for PH is
shown in Fig. 2.
At the time of referral, 38.1 % of the whole study
group and 45.6 % of the 90 patients with PH had active
malignant disease, which had no effect on the fully
adjusted odds of PH (p = 0.12). The tumor-related
prevalence values for both VTE and PE are included in
Table 2. Advanced cancer was defined as active disease
from solid tumors with at least N2 node involvement or
distant metastases. Among the 72 patients with a history
of VTE, 13 had advanced cancer [lung: 7, breast: 3,Fig. 2 The unadjusted risk of pulmonary hypertension (solid line)
with 95 % confidence intervals (dashed lines) among 72 cancer
patients with venous thromboembolism (VTE), expressed as a
function of the time interval between the first VTE episode and
Doppler echocardiography. The time axis is plotted on a logarithmic
scale to account for the wide range of time intervals and to better
illustrate the effect of recent VTE on the risk of PH
Table 2 Prevalence of venous thromboembolism (VTE) and
documented pulmonary embolism (PE) according to tumor group
VTE (n = 68) PE (n = 45)
Lung cancer 11/122 (9.0) 6/122 (4.9)
Breast cancer 16/113 (14.2) 8/113 (7.1)
Prostate cancer 6/57 (10.5) 5/57 (8.8)
Colorectal cancer 9/37 (24.3) 7/37 (18.9)
Other solid tumors 12/109 (11.0) 7/109 (6.4)
Lymphomas 8/67 (11.9) 7/67 (10.4)
Other hematologic malignancies 6/17 (35.3) 5/17 (29.4)
Figures in parenthesis are percentages. The analysis was limited to the 522
patients with one tumor entity
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Advanced cancer was also diagnosed in 26 of the 90 pa-
tients with PH [lung: 17, breast: 2, colon: 2, pancreas: 2,
ovary: 1, prostate: 1, mesothelioma: 1]. The prevalence
values of PH according to 5 treatment groups are shown
in Table 3.
Discussion
Among cancer patients, a history of VTE was associated
with a 2-fold increase in the odds of developing PH.
Although it is tempting to emphasize the higher impact
of PE on the risk of PH, we must acknowledge that the
composite item VTE was selected as the primary
predictor variable when designing this study for the
following reasons: Treatment for VTE is usually initiated
without requiring lung imaging when a DVT diagnosis
is made via peripheral venous imaging. Therefore,
several patients diagnosed with DVT only may also have
developed PE. Conversely, a search for DVT is notTable 3 Prevalence of pulmonary hypertension according to
treatment group
Treatment group Pulmonary hypertension
1: No previous antineoplastic chemotherapy
or chest radiotherapy (n = 345)
53 (15.4 %)
2: Previous chemotherapya without
anthracyclines (n = 114)
18 (15.8 %)
3: Previous chemotherapy with
anthracyclines (n = 79)
11 (13.9 %)
4: Previous chest radiotherapy from
1995 onwards (n = 74)
10 (13.5 %)
5: Pre-1995 chest radiotherapy (n = 23) 8 (34.8 %)
aAlkylating agents, antimetabolites, microtubule-targeting agents, molecular-
targeting agents. The treatment groups were not distinct from each other.
Hence, no between-group comparisons could be made. The high proportion
of patients with PH in group 5 probably relates to the high prevalence of atrial
fibrillation and left heart disease among the 23 patients who had undergone
pre-1995 radiotherapy (atrial fibrillation, 21.7 %; impaired left ventricular
systolic function, 8.7 %; significant valvular heart disease, 34.8 %; left ventricular
hypertrophy, 30.4 %)mandatory in patients with documented PE because
therapy of DVT and PE is the same. In the latter
condition, the whole peripheral thrombus can dislodge
from the venous wall and embolise. Both of these factors
lead to an underestimation of the DVT prevalence
among the VTE group.
The entry criteria of this study are critical in interpreting
its results. The presence of pulmonary or cardiac symp-
toms was a prerequisite for entering the protocol. A
patient with previous VTE who did not develop PH was
more likely to be asymptomatic and was therefore less
likely to be included in this study. Because of this referral
bias, our study overestimated the strength of the relation-
ship between a history of VTE and the presence of PH
relative to the overall population of patients with both
cancer and VTE which accounts for the high prevalence
of PH among patients with VTE.
The effects of severe airway obstruction and older age
on the odds of PH observed in this study were con-
sistent with previous work. Pulmonary artery systolic
pressure increases with age, and PH is common in the
setting of advanced chronic obstructive pulmonary
disease [10–12]. Pulmonary artery systolic pressure is
also determined by the left ventricular filling pressure.
Therefore, significant mitral or aortic valve disease, left
ventricular hypertrophy and atrial fibrillation were each
associated with a greater odds of PH. Atrial fibrillation
may be a consequence of PH [13]. In this study group,
however, there were only 8 patients with PH and atrial
fibrillation who had neither left heart disease nor severe
airway obstruction. Therefore, PH was the sole cause of
atrial fibrillation in only a few of our patients. We unex-
pectedly observed no significant impact of impaired left
ventricular systolic function on the odds of PH. Sample
size problems may partially account for this negative
result, which should be interpreted with caution. Only
35 patients (6.0 %) exhibited impaired left ventricular
systolic function, although 98 patients (16.8 %) received
anthracycline-based chemotherapy or pre-1995 radio-
therapy of the chest, both of which are detrimental to
the heart.
The association between a history of VTE and PH and
a diagnosis of PH are less relevant in patients with a
short life expectancy secondary to metastatic disease. In
this study, only 18.1 % of the 72 patients with a history
of VTE and 28.9 % of the 90 patients with PH had
advanced cancer; therefore, our results are relevant to
patients with less advanced active malignant disease or a
history of cancer.
A definite PH diagnosis requires right heart cath-
eterization, but this study could not have been com-
pleted using invasive techniques. This study relied on
Doppler echocardiography to diagnose PH. A peak
systolic pressure gradient across the tricuspid valve of
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To avoid diagnosing PH of questionable significance, we
changed the threshold to 35 mmHg in this study. We
did not add an estimated right atrial pressure to this gra-
dient to approximate pulmonary artery systolic pressure
because the estimation of right atrial pressure via the
compressibility of the inferior vena cava is often unreli-
able among patients with advanced lung disease [15, 16].
In this study, the overall prevalence of lung disease was
62.1 %, and 9.7 % of patients had severe airway obstruction.
This monocenter study had further limitations. First,
echocardiographic estimates of the peak systolic pressure
gradient across the tricuspid valve may have been
inaccurate due to poor visualization of the tricuspid
regurgitation jet, particularly in patients with advanced
chronic obstructive pulmonary disease. PH is not always
accompanied by an analyzable tricuspid regurgitation jet;
therefore, we missed several patients with this condition.
Second, the imaging techniques for diagnosing and
excluding of VTE are imperfect and vary in quality
between institutions. However, as these two limitations
apply to both patients with and without VTE, they tend
to dilute the impact of VTE on the odds of PH and
therefore paradoxically do not weaken the strength of
our findings. Third, diastolic dysfunction contributes to
PH and is common following mediastinal irradiation
[17]. We did not include parameters pertaining to dia-
stolic left ventricular function in the regression analysis
because tissue Doppler imaging was not available at our
institution before 2008. The assessment of transmitral
flow curves via Doppler echocardiography cannot be
used to reliably diagnose diastolic dysfunction. Given the
significant effect of left ventricular hypertrophy on the
odds for PH, we hypothesize that many of our patients
with this condition had left ventricular diastolic dysfunc-
tion. Fourth, this study does not provide data on the
prognostic impact of PH in cancer patients with pre-
vious VTE. Fifth, the small sample size of the PH sub-
group precluded determining whether treatment-related
factors interacted with the risk for PH, such as endo-
crine therapies, previous administration of chemo-
therapeutic agents implicated in lung injury, the time
intervals between a wide range of chemotherapies and
referral, and the type and duration of anticoagulant ther-
apy following VTE. Similarly, the numbers of patients in
the 6 tumor groups presented in Table 2 were too low
for any attempts to determine the sites and stages of
cancer that predispose to PH following VTE. Sixth,
although all patients were interviewed for a history of
VTE in a standardized manner and these data were
checked with their medical records, we may have missed
some patients who had been diagnosed with VTE at other
institutions but did not recall that. Finally, we did not per-
form lung imaging tests on all patients with VTE and PHin this hypothesis-generating study; therefore, we lack data
regarding the prevalence of findings suggestive of CTPH
in this subgroup. This warrants further investigation.
Patients with unprovoked VTE are at an excess risk of
receiving a subsequent diagnosis of cancer. Most tumors
are diagnosed within the first 6 months after an episode
of unprovoked VTE and the incidence rate of cancer
declines to that in the general population at 12 months
[18]. In our cohort, 58.8 % of the 34 VTEs preceding or
coinciding with the diagnosis of the first tumor occurred
more than 12 months before the cancer diagnosis was
made, as shown in Fig. 1. However, it was impossible to
ascertain from the historical data available to us how
many of these VTEs were unprovoked, especially in
patients with a history of remote VTE [19].
In the setting of an uncomplicated, acute PE, the risk
of PH should rapidly decrease with time due to anti-
coagulant treatment. Figure 2 demonstrates that the risk
of PH did not depend on the time interval between VTE
and Doppler echocardiography. The association between
a history of VTE and PH remained significant following
the exclusion of the 3 patients with VTE within 1 month
of referral. Therefore, transient PH secondary to uncom-
plicated PE cannot account for our findings. The median
time interval of 43 months between VTE and referral is
suggestive of the presence of a long-lasting obstruction
within the pulmonary vascular bed following VTE. All
patients included in this study had cardiac or pulmonary
symptoms. It can be assumed that PH contributed to
these symptoms in many patients with this condition.
The long time interval between the diagnosis of the first
tumor and referral observed in the 19 patients with VTE
and PH [89 (46; 143) months] fits with registry data sug-
gesting that many CTPH-associated cancers are survived
several years before a diagnosis of CTPH is made [5].
In the general population, the cumulative incidence of
CTPH is 3.8 % at 24 months following the first PE, with
no further increase after more than 24 months of
follow-up [20]. Given the limitations of echocardiog-
raphy in the diagnosis of PH, this low incidence rate
cannot explain the 3-fold increase in the odds of PH fol-
lowing PE observed in this study, even when the above-
mentioned referral bias is taken into account. Beyond
patient- and treatment-related features, a number of bio-
logical factors may account for a link between cancer
and PH, such as the expression of hemostatic proteins,
the production of microparticles by tumor cells, the
presence of inflammatory cytokines, and the tumor cell
expression of adhesion molecules that bind platelets
which are activated in CTPH [21, 22]. Idiopathic
pulmonary arterial hypertension was referred to as a
localized form of cancer [23], because both conditions
share several features at the cellular level including pro-
liferation, hypertrophy and distal extension of smooth
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function, genomic instability and expression of cancer
biomarkers [24, 25]. Cancer might predispose to an
ongoing pulmonary vessel remodeling process that is
initiated by VTE, maintained by the above-mentioned
biological factors and results in persistent PH.
Our data suggest that PH after VTE is common among
cancer patients with cardiac or pulmonary symptoms.
Given the lack of a control group of non-cancer patients
with cardiac or pulmonary symptoms and a history of
VTE, however, this study provides no proof that this
finding is specific for cancer patients. The odds of PH may
be not be significantly lower in such a control group and
the only difference may be the higher prevalence of VTE
among the cancer patients reflecting the link between
cancer and the activation of the hemostatic system.
Because of our findings we recommend to screen
cancer patients with cardiac or pulmonary symptoms
and a history of VTE for PH, even if the VTE episode
occurred years before referral. Echocardiographic evi-
dence of PH should raise concern regarding the
presence of CTPH, particularly in younger symptomatic
patients without the above-mentioned pulmonary or
cardiac comorbidities associated with PH.
Conclusion
The results of this study suggest a link between a remote
or recent history of VTE and future PH in patients
presenting with dyspnea, cough, chest pain, pulse irregu-
larities, or exercise intolerance and either a history of can-
cer or active cancer. Our findings are not generalizable to
non-cancer patients and cancer patients without pul-
monary or cardiac symptoms after VTE due to referral
bias towards an increased prevalence of PH in the VTE
group of this study.
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